Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838938 | 0.84 | CA1 (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7040556 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TDP1KDM4EL3MBTL1MAPT | |
| SCHEMBL6203845 | 0.82 | CA1 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1526352 | 0.82 | CA1 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4586248 | 0.82 | TAAR1 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28069112 | 0.82 | CA1 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL12817362 | 0.81 | ALOX5 (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7664369 | 0.81 | NPC1 (0.37) | TAAR1PTGS2 | |
| SCHEMBL5335645 | 0.80 | ALOX5 (0.49) | PTGS2DRD2DRD3ALOX5 | |
| SCHEMBL17046337 | 0.80 | L3MBTL1 (0.39) | SMN1; SMN2ALDH1A1TSHRTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2020-08-27 | — | — | US | claimed |
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2017-07-20 | — | — | US | claimed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | claimed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | claimed |
| US-20150099636-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-04-09 | — | — | US | claimed |
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | claimed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | claimed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | claimed |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2012-12-13 | — | — | US | claimed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | claimed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | RHEOGENE, INC. (DE CORPORATION) | 2004-09-02 | — | — | US | claimed |
| EP-0986560-B1 | PYRROLO 2,1,5-CD]INDOLIZINE DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | KAROBIO AB (SE) | 2004-03-24 | — | — | EP | claimed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | claimed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2003105849-A1 | TETRAHYDROQUINOLINES FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2003-12-24 | — | — | WO | claimed |
| US-20030109705-A1 | Novel cyanoenamines useful as ligands for modulating gene expression in plants or animals | SYNGENTA PARTICIPATIONS AG (CH) | 2003-06-12 | — | — | US | claimed |
| EP-0982292-B1 | Process for the preparation of monoacylhydrazines using carboxylic acids | DOW AGROSCIENCES LLC (US) | 2003-03-26 | — | — | EP | claimed |
| US-6096890-A | Process for substituted hydrazides using carboxylic acids | ROHM AND HAAS COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| EP-0982292-A2 | Process for the preparation of monoacylhydrazines using carboxylic acids | ROHM AND HAAS COMPANY (US) | 2000-03-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204079-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | CA1 2422/4885CA2 3649/4885CA7 2680/4885 |
| US-20200270225-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | CA1 2422/4885CA2 3649/4885CA7 2680/4885 |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | NR2E3, ESRRB, NR0B2 | CA1 4759/4885CA2 4557/4885CA7 4815/4885 |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | CA1 4357/4885CA2 4537/4885CA7 4382/4885 |
| US-20120316066-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | CA1 2422/4885CA2 3649/4885CA7 2680/4885 |
| US-20150099636-A1 | Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, CRYZ, TCF12 | CA1 2422/4885CA2 3649/4885CA7 2680/4885 |
| US-20030109705-A1 | Novel cyanoenamines useful as ligands for modulating gene expression in plants or animals | ACSL1, ACVRL1, DCLK3 | CA1 3378/4885CA2 2937/4885CA7 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.